NOVETUDE SANTE PRO I : revenue, balance sheet and financial ratios

In 2025, NOVETUDE SANTE PRO I achieves revenue of 3.6 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +20.2%. Vs 2024, growth of +21% (3.0 M€ -> 3.6 M€). After deducting consumption (-23 k€), gross margin stands at 3.6 M€, i.e. a rate of 101%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 167 k€, representing 4.6% of revenue. Warning negative scissor effect: despite revenue change (+21%), EBITDA varies by -56%, reducing margin by 8.0 pts. This reflects costs rising faster than revenue. The operating margin remains fragile, requiring cost vigilance. Net income is negative at -2.2 M€ (-61.3% of revenue), which will impact equity.

The debt ratio (= Financial debt / Equity x 100) stands at 7%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 7.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

The liquidity ratio (= Current assets / Current liabilities) stands at 167.99. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 82.0x. Operating income very largely covers interest expenses: high safety margin.

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 31 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 229 days. Excellent situation: suppliers finance 198 days of the operating cycle (retail model). Inventory turnover is 2 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 769 days of revenue, i.e. 7.7 M€ to permanently finance. Over 2016-2025, WCR increased by +217%, requiring additional financing.

Based on 412 transactions of similar company sales (all years), the value of NOVETUDE SANTE PRO I is estimated at 702 945 € (range 321 954€ - 1 482 999€). With an EBITDA of 167 021€, the sector multiple of 3.0x is applied. The price/revenue ratio is 0.29x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.